Microdosing

§ 00What Is Microdosing

A microdose is a sub-perceptual dose — typically one tenth to one twentieth of a full recreational or therapeutic dose. At this level, no hallucinations, ego softening, or obvious altered state occurs. The person taking it should, in principle, be able to drive, work, and hold a conversation normally.

The practice became widely discussed after James Fadiman’s 2011 book and his ongoing collection of self-reports, and it has since attracted both clinical interest and significant overclaiming. The current state of evidence is somewhere between promising and unproven, and this guide tries to reflect that honestly.

Microdosing is not a route to a psychedelic experience. It is not equivalent to taking a small recreational dose. It is a separate practice with its own logic, its own protocols, and its own failure modes.

§ 01Dose Range

All figures below apply to dried Psilocybe cubensis by weight. Potency varies between strains and batches; the ranges here are for a typical mid-potency cultivated variety.

The single most common mistake in microdosing is dosing too high. If you notice you are microdosing on a given day — if the world looks slightly brighter, if your thoughts feel faster, if people at work seem unusual — you are above the microdose threshold. Drop the dose, not the protocol.

Individual variation in sensitivity is large. Some people feel 0.1g clearly; others feel nothing at 0.3g. Start at the low end and adjust over several weeks, not days. High-potency strains (Penis Envy lineage, for example) warrant starting even lower.

§ 02Scheduling Protocols

The purpose of scheduled off-days is tolerance. Psilocybin tolerance builds in 24–48 hours and degrades over roughly the same period. A protocol without rest days stops working within a week as 5-HT_2A receptors downregulate.

Fadiman Protocol

One day on, two days off, repeating indefinitely. Day 2 is sometimes called an “afterglow day” — some users find it the most productive, possibly from mild receptor upregulation after the dose. Day 3 is a baseline return. The most widely studied protocol. Fadiman’s original recommendation was a 4–8 week trial with regular journaling.

Stamets Protocol

Four days on, three days off. Popularized by mycologist Paul Stamets, who pairs psilocybin with lion’s mane mushroom and niacin in what he calls the “Stamets Stack.” More frequent than Fadiman; some users find it more consistent, others accumulate tolerance by the end of the four-day run. Whether the stack components add anything beyond psilocybin alone is unestablished.

Every Other Day

Simple to track; tolerance is less managed than the Fadiman protocol. Works for some, drifts for others. Not widely studied.

Intuitive / As-Needed

Some people dose only when they feel they would benefit — before a demanding creative project, during a difficult emotional period. Less structured and harder to evaluate objectively. The risk is dose drift and using it to avoid discomfort rather than engage with it.

§ 03What the Evidence Says

The honest summary: microdosing is promising but not proven. The overwhelming majority of evidence is observational — surveys, self-reports, and naturalistic studies without controls. These are valuable but cannot distinguish the pharmacological effect from expectation.

The self-blinding study (Szigeti et al., 2021)

The most rigorous study to date. 191 participants self-blinded their own microdoses (capsules of varying content) and reported outcomes. Both active and placebo groups showed improvements in well-being; the active group showed slightly greater improvements on some measures. The researchers concluded that expectation accounts for a meaningful portion of reported benefits — but that a pharmacological signal may exist above the expectation floor.

Naturalistic surveys

Anderson et al. (2019) and Polito & Stevenson (2019) both found that microdosers reported improvements in mood, focus, and creativity, along with some negative effects — primarily over-stimulation, neuroticism, and disrupted sleep at the wrong dose or frequency. These studies have no control group.

What is not established

• Whether the benefits persist beyond 4–8 weeks of use
• The optimal dose or protocol for a given outcome
• Long-term safety beyond self-report
• Whether any specific condition (depression, ADHD, anxiety) responds better than others
• Whether the Stamets Stack components add anything

§ 04Screening

The contraindications for microdosing are the same as for full doses — the pharmacology is the same compound at a lower concentration.

• Schizophrenia, schizoaffective disorder, or bipolar I — hard contraindication
• First-degree relative with any of the above — strong caution
• Current or recent psychosis — hard contraindication
• SSRIs or SNRIs — blunting effect means dose creep risk; see the interactions guide
• Lithium — hard contraindication at any dose
• Anxiety as a primary condition — some people find microdosing amplifies anxiety. Start very low and monitor closely; stop if it worsens
• High-stress periods — the first few weeks of a protocol are not the time to start a demanding project or navigate a personal crisis

§ 05Practical Guidance

Starting

• Begin at 0.05–0.1g and hold that dose for at least two full protocol cycles before adjusting
• Grind your material to a consistent powder and weigh on a milligram-accurate scale — volume measurement is not reliable at these quantities
• Dose in the morning, not the evening — psilocybin has a stimulating profile for most people at sub-perceptual doses and will disrupt sleep if taken too late
• Do not dose before a high-stakes situation in the first few weeks. Understand your individual response first

Tracking

Keep a brief journal — not a daily essay, just a few lines. Record dose day, day after, and baseline day. Note mood, focus, sleep, and any negative effects. After 4 weeks, read back from the beginning. The pattern is often clearer in retrospect than it is in the moment.

Rate each day on a simple scale (1–5 mood, 1–5 energy) so you have something comparable. Narrative entries alone are hard to evaluate.

What to watch for

• Noticeable perceptual effects: dose is too high
• Increased anxiety or irritability in the days following a dose: consider lower dose or longer rest days
• Disrupted sleep: move dose earlier, or reduce dose
• Diminishing returns after several weeks: tolerance; take a break
• Using doses to avoid difficult emotions rather than process them: pause the protocol and sit with the feeling

§ 06Common Mistakes

Dosing too high

The most common. A 0.3–0.5g dose is a mini-dose, not a microdose. At that level you are not microdosing — you are having a mild psychedelic experience and trying to function through it. Drop the dose.

Skipping rest days

Dosing daily or every other day consistently builds tolerance. Within 7–10 days the same dose stops working. The rest days are the mechanism, not optional.

Expecting immediate effects

Microdosing is cumulative and subtle. People who expect to feel something the first day and don't will often raise the dose. The signal, if it exists, typically shows up over weeks in your journal, not on the first morning.

No baseline

Starting without tracking your mood and functioning before you begin means you have nothing to compare to. The placebo effect is strong. Journal before you start.

Continuing past diminishing returns

Some people keep adding weeks to their protocol past the point of benefit because stopping feels uncertain. 4–8 weeks is enough for an initial evaluation. Stop, wait 4 weeks, reassess.

Treating it as a substitute for therapy or medication

Microdosing is an adjunct practice, not a replacement for a prescriber, a therapist, or other evidence-based treatment. Using it to avoid getting proper help is a harm in itself.

§ 07Cycling & Stopping

Most practitioners recommend treating microdosing in bounded cycles rather than as an ongoing supplement. A typical structure:

• 4–8 weeks on a protocol, with daily journaling
• 2–4 week break before deciding whether to continue
• Honest evaluation: are the metrics in your journal better than baseline? Are you using it to avoid something?

Tolerance builds across cycles even with rest days built in. A month off allows full receptor normalization. Some people find a single well-structured cycle is sufficient; others use seasonal cycles. There is no evidence supporting indefinite daily use.

For the tolerance curve and a tool for estimating equivalent doses after recent use, see the tolerance & recovery page.

§ 08Legal Context

Psilocybin is a Schedule I controlled substance under US federal law. Microdosing confers no legal protection — possession of any quantity is a federal offense, and state-level decriminalization applies to personal possession generally, not specifically to microdosing.

Oregon (Measure 109) and Colorado (Proposition 122) have regulated therapeutic frameworks; these do not create a legal retail pathway for self-directed microdosing. For a full state-by-state breakdown, see the legal status reference.

§ 09Sources

• Fadiman, J. (2011). The Psychedelic Explorer’s Guide.Park Street Press. The foundational text; Fadiman’s protocol is described here along with early self-reports.
• Polito, V. & Stevenson, R.J. (2019). “A systematic study of microdosing psychedelics.” PLoS ONE, 14(2). The first prospective longitudinal study; tracked 98 microdosers over six weeks.
• Anderson, T. et al. (2019). “Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.” Psychopharmacology, 236(2). Large-sample survey of self-identified microdosers.
• Szigeti, B. et al. (2021). “Self-blinding citizen science to explore psychedelic microdosing.” eLife, 10:e62878. The most controlled study to date; found expectation accounts for a significant portion of reported benefit.
• Webb, M., Copes, H., & Hendricks, P.S. (2019). “Narrative identity, rationality, and microdosing classic psychedelics.” International Journal of Drug Policy, 70. Qualitative study of how microdosers frame and justify the practice.